Seroquel in Bipolar Depression Versus SSRI

NCT ID: NCT00119652

Last Updated: 2013-01-04

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

676 participants

Study Classification

INTERVENTIONAL

Study Start Date

2005-05-31

Study Completion Date

2007-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine whether quetiapine is effective and safe in the acute treatment of bipolar depression and whether the effect is maintained when treatment is continued.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Bipolar Disorder Bipolar Depression Depression

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

quetiapine fumarate (Seroquel)

Intervention Type DRUG

paroxetine

Intervention Type DRUG

mood stabilizing activity

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male and female out-patients aged 18 to 65 years inclusive
* Diagnosis of Bipolar Disorder (Bipolar I or Bipolar II), most recent episode depressed

Exclusion Criteria

* Current period of depression lasting less than 4 weeks or more than 12 months
* Use of prohibited medication
* Substance or alcohol dependence or abuse
* Current suicide risk or suicide attempt within 6 months
* Breast feeding or pregnancy
* Clinically relevant disease or clinical finding
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

AstraZeneca

INDUSTRY

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

AstraZeneca Seroquel Medical Science Director, MD

Role: STUDY_DIRECTOR

AstraZeneca

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Research Site

Phoenix, Arizona, United States

Site Status

Research Site

Little Rock, Arkansas, United States

Site Status

Research Site

National City, California, United States

Site Status

Research Site

San Clemente, California, United States

Site Status

Research Site

San Diego, California, United States

Site Status

Research Site

Maitland, Florida, United States

Site Status

Research Site

Winter Park, Florida, United States

Site Status

Research Site

Atlanta, Georgia, United States

Site Status

Research Site

Smyrna, Georgia, United States

Site Status

Research Site

Northfield, Illinois, United States

Site Status

Research Site

Oak Brook, Illinois, United States

Site Status

Research Site

New Orleans, Louisiana, United States

Site Status

Research Site

Shreveport, Louisiana, United States

Site Status

Research Site

Glen Burnie, Maryland, United States

Site Status

Research Site

St Louis, Missouri, United States

Site Status

Research Site

Clementon, New Jersey, United States

Site Status

Research Site

New York, New York, United States

Site Status

Research Site

Raleigh, North Carolina, United States

Site Status

Research Site

Cincinnati, Ohio, United States

Site Status

Research Site

Dayton, Ohio, United States

Site Status

Research Site

Oklahoma City, Oklahoma, United States

Site Status

Research Site

Philadelphia, Pennsylvania, United States

Site Status

Research Site

Austin, Texas, United States

Site Status

Research Site

Dallas, Texas, United States

Site Status

Research Site

Irving, Texas, United States

Site Status

Research Site

Richmond, Virginia, United States

Site Status

Research Site

Bellevue, Washington, United States

Site Status

Research Site

Kirkland, Washington, United States

Site Status

Research Site

Brisbane, Queensland, Australia

Site Status

Research Site

Everton Park, Queensland, Australia

Site Status

Research Site

Southport, Queensland, Australia

Site Status

Research Site

Epping, Victoria, Australia

Site Status

Research Site

Malvern, Victoria, Australia

Site Status

Research Site

Providencia Santiago, , Chile

Site Status

Research Site

Santiago, , Chile

Site Status

Research Site

Bogotá, , Colombia

Site Status

Research Site

San José, , Costa Rica

Site Status

Research Site

Athens, , Greece

Site Status

Research Site

Thessaloniki, , Greece

Site Status

Research Site

Tripoli, , Greece

Site Status

Research Site

México, , Mexico

Site Status

Research Site

Yucatán, , Mexico

Site Status

Research Site

Lima, , Peru

Site Status

Research Site

San Borja, , Peru

Site Status

Research Site

Bucharest, , Romania

Site Status

Research Site

Galati, , Romania

Site Status

Research Site

Iași, , Romania

Site Status

Research Site

Măgura, , Romania

Site Status

Research Site

Benoni, , South Africa

Site Status

Research Site

Cape Town, , South Africa

Site Status

Research Site

Durban, , South Africa

Site Status

Research Site

Pretoria, , South Africa

Site Status

Research Site

Gaziantep, , Turkey (Türkiye)

Site Status

Research Site

Istanbul, , Turkey (Türkiye)

Site Status

Research Site

Manisa, , Turkey (Türkiye)

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Australia Chile Colombia Costa Rica Greece Mexico Peru Romania South Africa Turkey (Türkiye)

References

Explore related publications, articles, or registry entries linked to this study.

McElroy SL, Weisler RH, Chang W, Olausson B, Paulsson B, Brecher M, Agambaram V, Merideth C, Nordenhem A, Young AH; EMBOLDEN II (Trial D1447C00134) Investigators. A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II). J Clin Psychiatry. 2010 Feb;71(2):163-74. doi: 10.4088/JCP.08m04942gre. Epub 2010 Jan 26.

Reference Type DERIVED
PMID: 20122366 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

D1447C00134

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Pediatric Bipolar Depression
NCT00811473 COMPLETED PHASE3